PATENT CLAIM ANALYSIS

Application Number: 15934334
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "133100"]

Abstract:
Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

Claim (Index 12):
The method of  claim 11  which comprises one or more of the following:\n (i) it enhances Th1 immunity; \n (ii) it promotes the proliferation or survival of antigen-specific T cells; \n (iii) it promotes the proliferation or survival of antigen-specific CD8 +  T cells; \n (iv) it promotes the proliferation or survival of antigen-specific CD8 +  effector cells, or memory cells; \n (v) it results in the generation of antigen-specific memory T cells; \n (vi) it includes the administration of antigen; \n (vii) the administered anti-CD27 antibody or antigen binding fragment promotes the expansion of T cells in an antigen-dependent manner; \n (viii) the administered anti-CD27 antibody or antigen binding fragment is selected from a human antibody, primate antibody, chimeric antibody, humanized antibody, primatized antibody and single chain antibody; \n (ix) the administered anti-CD27 antibody or antigen binding fragment is engineered to modify (enhance or diminish) at least one antibody effector function; \n (x) the administered anti-CD27 antibody or antigen binding fragment (1) lacks glycosylation, \n (xi) the administered anti-CD27 antibody or antigen binding fragment is modified to alter Fc glycosylation, (3) it comprises one or more Fc residue modifications, (4) it is modified to enhance or diminish binding to a specific FcR or (5) it comprises a combination of the foregoing modifications; \n (xii) the administered anti-CD27 antibody or antigen binding fragment is modified to enhance or inhibit FcRn binding; \n (xiii) the administered anti-CD27 antibody or antigen binding fragment comprises modifications that are selected from (1) modifications that reduce or enhance interaction with proteins of the complement system, or (2) modifications which reduce undesirable toxicity; \n (xiv) the administered anti-CD27 antibody or antigen binding fragment is modified to inhibit toxicity elicited by release of cytokines; \n (xv) the administered anti-CD27 antibody or antigen binding fragment contains at least one of human IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD and IgE constant domains; \n (xvi) the administered anti-CD27 antibody or antigen binding fragment is an intact antibody selected from a group consisting of an intact IgG1 antibody, an intact IgG2 antibody, an intact IgG3 antibody, an intact IgG4 antibody, and intact IgM antibody, an intact IgA1 antibody, an intact IgA2 antibody, an intact secretory IgA antibody, an intact IgD antibody, or an intact IgE antibody; \n (xvii) the administered anti-CD27 antibody or antigen binding fragment is used to treat a condition selected from cancer, infectious disease, inflammatory condition, autoimmune disease, and allergic condition; \n (xviii) the administered anti-CD27 antibody or antigen binding fragment is used to treat an infectious disease caused by a bacterium, virus, mycobacterium, fungus, yeast or a parasite. \n (xix) the administered anti-CD27 antibody or antigen binding fragment is used to treat an infectious disease caused by a parasite selected from  Babesia  sp.,  Entomoeba  sp,  Giarda  sp,  Plasmodium  sp,  Leishmania  sp,  Trypanosome  sp,  Toxoplasma  sp, flatworm and round worm parasites; or a bacterium is selected from  Escherichia, Staphylococcus, Pseudomonas, Streptococcus, Campylobacter, Listeria, Clostridium, Pasteurella, Pseudomonas, Neisseria, Enterococcus, Klebsiella, Heliobacter, Listeria, Salmonella, Corynebacterium, Haemophilus, Pasteurella, Bacteroides, Fusobacterium, Streptobacillus, Treponema, Leptospira, Rickettsia , and  Actinomyces  or a virus is selected from a retrovirus, picornavirus, enterovirus, hepatitis, poliovirus, Coxsackie's virus, rhinovirus, echovirus, Calciviridae, Togaviridae, Flaviviridae, Rhabdoviridae, Coronaviridae, Paramyxoviridae, Orthomyxoviridae, Filoviridae, Bungaviridae, Reoviridae, Adenoviridae, Bimaviridae, Papovaviridae, Herpeviridae, Iridoviridae, and unclassified viruses; or a fungus selected from  Aspergillus, Coccidoides, Blastomyces, Histoplasma, Chlamydia, Nocardia , and  Pneumocytis;  \n (xx) the administered anti-CD27 antibody or antigen binding fragment is used to treat a cancer selected from lymphoma, leukemia, chronic lymphocytic leukemia, breast cancer, prostate cancer, colon cancer, bone cancer, pancreatic cancer, stomach cancer, liver cancer, cervical cancer, bladder cancer, testicular cancer, kidney cancer, lung cancer (small and large cell), brain cancer, retinoblastoma, esophageal cancer, eye cancer, head and neck cancer, endometrial cancer, larynx cancer, melanoma, neuroblastoma, neuroblastoma, thyroid cancer, rhabdosarcoma, oral cavity cancer, uterine cancer, ovarian cancer, sarcoma, connective tissue cancer and skin cancer; \n (xxi) the administered anti-CD27 antibody or antigen binding fragment is used to treat an autoimmune disease selected from multiple sclerosis, diabetes, psoriasis, Crohn's disease, inflammatory bowel disease, SLE, myasthenia gravis, Goodpasture's syndrome, ITP, Graves disease, hemolytic anemia, rheumatoid arthritis, Hashimoto's thyroiditis, scleroderma, and Addison's disease; \n (xxii) the administered anti-CD27 antibody or antigen binding fragment is administered in a subject that is further administered a vaccine and the anti-CD27 antibody or antigen binding fragment enhances the immune response elicited by said vaccine; \n (xxiii) the administered anti-CD27 antibody or antigen binding fragment is administered in a subject that is further administered an antitumor vaccine and the anti-CD27 antibody or antigen binding fragment enhances the antitumor immune response elicited by said vaccine; \n (xxiv) the administered anti-CD27 antibody or antigen binding fragment is administered to a subject that is further administered a vaccine for affording immunity against an infectious agent and the anti-CD27 antibody or antigen binding fragment enhances the immune response elicited by said vaccine against the infectious agent optionally selected from a bacterium, a virus, a yeast, a fungus, a mycobacteria, or a parasite; \n (xxv) the administered anti-CD27 antibody or antigen binding fragment is administered in conjunction with at least one antigen or allergen; \n (xxvi) the administered anti-CD27 antibody or antigen binding fragment is administered before, after or in conjunction with a vaccine composition or is combined with the vaccine as a combined composition, optionally wherein the vaccine is a viral vaccine that confers immunity to a virus selected from a hepatitis, HIV, picornavirus, poliovirus, enterovirus, human Coxsackie virus, influenza virus, rhinovirus, echovirus, rubella virus, encephalitis virus, rabies virus, herpes virus, papillomavirus, polyoma virus, RSV, adenovirus, yellow fever virus, dengue virus, parainfluenza virus, hemorrhagic virus, pox virus, varicella zoster virus, parainfluenza virus, reovirus, orbivirus, rotavirus, parvovirus, African swine fever virus, measles, mumps, and Norwalk virus or the vaccine is a bacterial vaccine that confers immunity to a bacterium selected from  Pasteurella, Escherichia, Staphylococcus, Streptococcus, Salmonella, Heliobacter, Mycobacteria, Campylobacter, Enterococcus, Clostridium, Corynebacterium, Treponema, Bacteroides, Fusobacterium, Fusobacterium, Neisseria, Bacillus, Enterobacter, Streptobacillus, Leptospira, Haemophilus, Borrelia, Legionella, Erysipelothrix , and  Listeria  or the vaccine is specific to a parasite elected from  Babesia, Entomoeba, Giarda, Leishmania, Plasmodium, Toxoplasma, Trypanosome , round worm and flat worm; \n (xxvii) the administered administered anti-CD27 antibody or antigen binding fragment elicits enhanced CD8 +  T cell proliferation, survival and/or cytotoxic lymphocyte lytic (CTL) response in a subject in need thereof; \n (xxviii) the administered anti-CD27 antibody or antigen binding fragment is administered in combination with another therapeutic moiety, optionally wherein said other moiety is selected from the group consisting of another immune agonist, antibody, cytokine, chemotherapeutic, immunomodulator and immunostimulant; \n (xxix) the administered anti-CD27 antibody or antigen binding fragment is administered together with a second immune agonist and an antigen specific to a desired target, optionally a tumor; \n (xxx) the administered anti-CD27 antibody or antigen binding fragment is administered together with a second immune agonist and an antigen specific to a desired target, selected from the group consisting of a tumor associated peptide (TAA), tumor lysate, apoptotic tumor cells, and tumor-antigen carrying dendritic cells; \n (xxxi) the administered anti-CD27 antibody or antigen binding fragment is administered together with a second immune agonist and an antigen specific to a melanoma and the combination enhances (boosts) the immune response elicited against the tumor cells which express the target melanoma antigen; \n (xxxii) the administered anti-CD27 antibody or antigen binding fragment is administered together with another moiety selected from the group consisting of an immune stimulatory antibody or protein (positive costimulant), an immune antibody or protein that acts as a negative costimulant, an antibody or other moiety that blocks inhibitory signals to T cells and an antibody that binds to tumor cells or vasculature or stoma; or \n (xxxiii) the administered anti-CD27 antibody or antigen binding fragment is administered together with another moiety selected from the group consisting of an anti-CD40 antibody, an anti-OX40 antibody, an anti-4-1BB antibody, an anti-CD70 antibody, an anti-B7.1 antibody, an anti-B7.2 antibody, an anti-CTLA-4 antibody, an anti-CD28 antibody, a moiety that depletes or blocks regulatory T cells, and a cytokine.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 90.0
- Lexical Diversity: 1.64835
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13905436', '12446322', '14974793', '11743978', '13165154']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8595321209466389
- 35 USC 102 Novelty (BERT): 0.5970316109745805
- Combined Prediction Score: 0.833282069949433
- Mean Citation Score: 598.1939679999998
- Max Citation Score: 691.5565
- Similarity Product: 436.15387950730326

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test